Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Capital Expenditures (2020 - 2024)

Celularity (CELU) has disclosed Capital Expenditures for 5 consecutive years, with $91000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Capital Expenditures fell 84.31% to $91000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $161000.0, a 84.64% decrease, with the full-year FY2024 number at $161000.0, down 84.64% from a year prior.
  • Capital Expenditures was $91000.0 for Q4 2024 at Celularity, up from $49000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $9.4 million in Q4 2020 to a low of -$631000.0 in Q4 2021.
  • A 5-year average of $719647.1 and a median of $61000.0 in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 406.62% in 2022; the steepest drop was 1331.43% in 2022.
  • Celularity's Capital Expenditures stood at $9.4 million in 2020, then tumbled by 106.73% to -$631000.0 in 2021, then soared by 47.54% to -$331000.0 in 2022, then skyrocketed by 275.23% to $580000.0 in 2023, then tumbled by 84.31% to $91000.0 in 2024.
  • Per Business Quant, the three most recent readings for CELU's Capital Expenditures are $91000.0 (Q4 2024), $49000.0 (Q3 2024), and $10000.0 (Q2 2024).